Savara Secures $75M in Additional Debt Funding Upon FDA Approval of MOLBREEVI
ByAinvest
Tuesday, Jan 27, 2026 8:08 am ET1min read
HTGC--
SVRA--
Savara Inc., a biopharmaceutical company, has amended its loan agreement with Hercules Capital, allowing for up to $75 million in additional debt funding upon FDA approval of MOLBREEVI, a therapy for autoimmune pulmonary alveolar proteinosis. The amended agreement strengthens Savara's balance sheet and liquidity, enabling the company to support potential launch activities with non-dilutive capital. The FDA resubmitted the MOLBREEVI Biologics License Application in December 2025, with potential approval in 3Q 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet